TEM241220P43000
- 4.14
- +0.46+12.50%
Tempus AI Newsroom
Personalis and Tempus AI Extend Commercial Deal to Biopharma Industry
Express News | Personalis and Tempus Expand Collaboration to Biopharma
Insiders Own 36% of Tempus AI, Inc (NASDAQ:TEM) in Spite of Selling Recently and the Recent Dip May Have Hurt Them
With A 40% Price Drop For Tempus AI, Inc (NASDAQ:TEM) You'll Still Get What You Pay For
Insider Sale: EVP and General Counsel of $TEM (TEM) Sells 3,900 Shares
Tempus AI(TEM.US) Officer Sells US$3.94 Million in Common Stock
Tempus AI(TEM.US) Officer Sells US$5.1 Million in Common Stock
Tempus AI(TEM.US) Officer Sells US$3.51 Million in Common Stock
Tempus AI Is Maintained at Neutral by B of A Securities
Express News | Tempus AI Inc : BofA Global Research Raises Price Objective to $54 From $52
Tempus AI Price Target Announced at $60.00/Share by Wolfe Research
BofA Securities Maintains Tempus AI(TEM.US) With Hold Rating, Cuts Target Price to $54
Wolfe Research Initiates Tempus AI(TEM.US) With Buy Rating, Announces Target Price $60
Tempus AI(TEM.US) 10% Shareholder Sells US$79.76 Million in Common Stock
Insider Sale: 10% Owner at $TEM (TEM) Sells 130,016 Shares
Tempus AI(TEM.US) 10% Shareholder Sells US$17 Million in Common Stock
Tempus AI Insider Sold Shares Worth $16,997,810, According to a Recent SEC Filing
Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company
Cathie Wood's ARK Investment Bought 424.5K Shares of Tempus AI Today
Top Gap Ups and Downs on Wednesday: MLI, MSTR, GSK and More